Abstract
Taken together with electrophysiological data, these results suggest that in states of DA deficiency, systemically administered L-dopa or DA agonist drugs inhibit cell firing in the major output nuclei of the basal ganglia (GPI and SNPR). We propose that DA produces this net effect by a direct influence on the striato-GPI and striato-SNPR neurons, as well as indirectly via the striato-GPE-STN-GPI/SNPR circuit. The RCGU data suggest that DA activates the direct pathway by stimulating D1 receptor-bearing striatal GABAergic neurons projecting to GPI and SNPR. Supportive evidence includes the ability of D1 agonists to facilitate GABA release in the striatum and to increase the firing rates of striatonigral neurons. The RCGU data also support a net stimulatory action of DA on the GPE output on STN, consistent with the excitatory effects of DA on GPE neuronal firing rates. This effect may be mediated by both D1 and D2 receptors. Stimulation of this pathway should physiologically inhibit the STN resulting in dysfacilitation of the GPI and SNPR. According to this scheme, DA exerts complementary actions via both direct and indirect anatomical pathways to decrease tonic firing rates of intrinsic neurons in the major output nuclei of the basal ganglia (i.e., GPI and SNPR).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.